Products

AESARA HEOR Benchmarking Report: 2024

Insights on how Biopharma companies rank among their peers, strengths and weaknesses of HEOR organizations, and areas for improvement in value and evidence generation to enable patient access

Rationale

  • Capability
    Health Economics and Outcomes Research (HEOR) in the biopharmaceutical industry has grown significantly in recent decades, emphasizing patient access to new medicines alongside regulatory approvals
  • Environment

    Increasing investments in HEOR capabilities are driven by stakeholder demands for timely evidence of product value worldwide

    Additionally, policy developments like the Inflation Reduction Act (IRA) and European Union Regulation on Health Technology Assessment (EU HTAR) necessitate flexible and updated responses from HEOR functions

  • Need

    To maintain efficiency and sustainability, HEOR Groups must optimize their structure, evidence generation efforts, and marketplace impact

    Benchmarking studies are an important input to HEOR future-proofing strategies; however, the most recent studies focused on Medical Affairs and Market Access and only had some HEOR components

This 2024 benchmark is based on qualitative and quantitative data from:

7

biopharmaceutical companies

60+

interviews conducted with HEOR leaders and team members worldwide

Interviewee representation from:

globe-globe 2

Global

USA@4x

US

European union@4x

EU

Japan@4x

Japan

Canada@4x

Canada

United Kingdom@4x

UK

Focus

Organization structure
and positioning

  • Overview of participating companies
  • Centralized vs decentralized structure
  • Company positioning: Clinical/Medical vs Commercial/Corporate
  • Dedicated US support
  • HEOR geographic markets
  • C-suite expectations
  • Dedicated TA leads
  • Platform functions and CoEs
  • Outsourcing HEOR studies
  • Organizational restructuring

Capabilities
and infrastructure

  • Budget
  • Core capabilities
  • Participation on Global/US
  • Product/Brand Teams
  • Value narrative support
  • SOPs/guidances
  • ICER engagement
  • AI and technology advancements
  • Policy and methods developments

Teams
characteristics

  • FTE per $B revenue
  • FTE per drug development phase
  • HEOR Team qualifications
  • Professional development
  • Titles and salaries
  • Reporting layers
  • Remote work

Ways of
working

  • Global/Local interactions
  • Cross-functional group interactions
  • Evidence generation planning
  • RWE
  • External stakeholders interactions
  • HEOR metrics
  • Role of professional societies

AESARA insights and
recommendations

Investment will include access to a final report including organization structure and positioning, team characteristics, capabilities and infrastructure, ways of working, AESARA insights, and recommendations

49K (enterprise wide access)

Unlock Industry Insights

Contact us

Fill out the form below, and we will be in touch shortly.